The lncrna signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

HIGHLIGHTS

• who: January and colleagues from the Wuhan University, China have published the research: The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma, in the Journal: (JOURNAL) of 22/05/2022
• what: The authors will explore the relationship ccRCC, cuproptosis, and lncRNA.
• how: Using these 11 lncRNAs the authors developed a risk prediction model that upon ROC curve C-index curve and survival analysis as well as other clinical indicators shows great applicability in patients with ccRCC. The results indicated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.